Sun Pharma Joins White House Initiative on U.S. Medicine Pricing
Sun Pharmaceutical Industries Ltd 路 Press Release 路 01 Sept 2026, 7:19 am
Sun Pharma Joins White House Initiative on U.S. Medicine Pricing On 01 Sep'26, Sun Pharma entered an agreement with the U.S. government to improve medicine affordability. The company will extend Most Favored Nation (MFN) pricing to state Medicaid programs and apply it to future innovative drug launches. In return, the U.S. will delay Section 232 tariffs on Sun Pharma's innovative products for over two years. The U.S. is the company's largest market, contributing approximately 27% to global revenue. This follows the firm's agreement to acquire Organon & Co. for $11.75 billion.
Original exchange filing (PDF)
More announcements from Sun Pharmaceutical Industries Ltd
- Intimation of Schedule of Analyst/Institutional Investor Meeting 路 05 Nov 2026
- Q2FY27 Earnings Call Transcript 路 05 Nov 2026
- Clarification regarding news report relating to the Company''s Assam facility 路 03 Nov 2026
- The Exchange has sought clarification from Sun Pharmaceutical Industries Ltd on November 2, 2026, with reference to news appeared in https://www.thehindu.com/ dated October 30, 2026 quoting .... 路 02 Nov 2026
- Completion and results of postal ballot dated 01 October 2026 路 01 Nov 2026
- Q2FY27- Investor Call Audio Recording 路 31 Oct 2026
- Board Meeting Outcome - Conclusion 路 30 Oct 2026
- Unaudited Financial Results for the quarter and half year ended 30 September 2026 路 30 Oct 2026
